Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, PMID: 32081463
Ocular Toxicity of Mirvetuximab, PMID: 30379722
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer, PMID: 32674207
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer, PMID: 29098867
Exploiting the folate receptor α in oncology, PMID: 32152484
Antibodies to watch in 2019, PMID: 30516432
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer, PMID: 32984932
Review of Immune Therapies Targeting Ovarian Cancer, PMID: 30430276
New treatments in ovarian cancer, PMID: 29232465
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine, PMID: 30413525
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer, PMID: 29424243
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer, PMID: 30093227
Folate Receptor α-Targeted 89 Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer, PMID: 31369274
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models, PMID: 27889646
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples, PMID: 28534292
Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics, PMID: 31098752
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors, PMID: 25904506
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors, PMID: 28440955
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study, PMID: 28029313
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine, PMID: 28843653
Antibody-drug conjugates for ovarian cancer: current clinical development, PMID: 30531606
Antibody-drug conjugates for the treatment of ovarian cancer, PMID: 32463296
Antibody-drug conjugates in gynecologic malignancies, PMID: 30929824
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I, PMID: 33667670
Antibodies to watch in 2018, PMID: 29300693
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments, PMID: 29116596
Novel therapeutics: response and resistance in ovarian cancer, PMID: 31462544
Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors, PMID: 30585545
Novel antibody-drug conjugates: current and future roles in gynecologic oncology, PMID: 32618744
Highlights of the NCCN Oncology Research Program, PMID: 30659135
Significant Activity for ADC in Ovarian Cancer, PMID: 34140289
Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast, PMID: 30268765
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer, PMID: 27797594
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers, PMID: 29440294
Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer, PMID: 33812984
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker., PMID:40508029
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters., PMID:40501953
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer., PMID:40501444
State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers., PMID:40489723
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Ovarian Cancer Therapy., PMID:40389314
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer., PMID:40270982
Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer., PMID:40242965
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial., PMID:40179908
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma., PMID:40150910
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics., PMID:40139025
A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer., PMID:40126684
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate., PMID:40121972
Addressing the challenge of platinum-resistant ovarian cancer: the role of mirvetuximab soravtansine., PMID:40109581
Mirvetuximab soravtansine: current and future applications., PMID:40102896
Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report., PMID:40050918
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial., PMID:40044930
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer., PMID:40029935
Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer., PMID:40028469
[Mirvetuximab soravtansine as monotherapy in platinum-resistant ovarian cancer expressing alpha folate receptor]., PMID:40016053
Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells., PMID:39996761
Mirvetuximab soravtansine shines post-PARP inhibitor progression: promising insights from the PICCOLO trial., PMID:39988550
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies., PMID:39970828
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective., PMID:39922351
Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines., PMID:39900344
Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine., PMID:39734248
Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis., PMID:39729462
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680
Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy., PMID:39640287
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers., PMID:39631181
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial., PMID:39617145
Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?, PMID:39595996
Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers., PMID:39590153
The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary., PMID:39461270
Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer., PMID:39378056
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen., PMID:39307840
Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature., PMID:39281842
Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)., PMID:39228525
[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]., PMID:39191683
Accuracy and Completeness of Large Language Models About Antibody-Drug Conjugates and Associated Ocular Adverse Effects., PMID:39110155
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer., PMID:39082675
Mirvetuximab after anaphylaxis to Paclitaxel: A case report., PMID:39076678
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer., PMID:39061184
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities., PMID:38941962
Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases., PMID:38914019
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial., PMID:38858103
Ocular toxicities associated with antibody drug conjugates., PMID:38814581
Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis., PMID:38788019
For research use only. Not for human or drug use.
